Why is Waldencast stock sliding today?
Waldencast stock fell 15.3% after announcing plans to delist from Nasdaq by October 2, 2026, and seek OTC quotation under the new ticker 'MLKM'. The company cited high U.S. listing costs and reduced need for public equity markets. The Nasdaq Composite and S&P 500 also declined, amplifying the selling pressure. The move is seen as a liquidity downgrade, potentially triggering forced selling by institutional funds.
How this was made
The 30-second read
Why it matters
The delisting removes a major source of institutional liquidity, likely triggering forced sales and widening spreads, which can depress the share price further.
Market read
A material corporate action with immediate price impact; traders should consider exiting or shorting the stock.
What to watch
Potential for a future reverse merger or private placement that could provide upside beyond the OTC transition.
Background
Waldencast (formerly Milk Makeup plc) cited high compliance costs and reduced need for US equity financing after selling its Obagi Medical division for $460 million.
Ticker impact
Waldencast announced a voluntary Nasdaq delisting and move to OTC, causing a 15.3% pre‑open price drop.
Expect further downside as institutional holders liquidate and bid‑ask spreads widen.
The filing is a primary disclosure of a delisting, a material corporate action that immediately reduces marketability.
Market effects
Other Nasdaq‑listed consumer‑health stocks may see heightened scrutiny over listing costs.
US small‑cap market may see modest bearish pressure from the delisting trend.
Limited; primarily affects Waldencast and similar OTC‑transition candidates.
Counterpoint
If the company successfully reduces debt and refocuses on private financing, the price could stabilize after the initial sell‑off.
Key entities
- CompanyWaldencast
Consumer‑health and beauty brand exiting Nasdaq.
- InvestorBridgepoint
Buyer of Waldencast's Obagi Medical division.
